]>

IRCT20200325046854N1 IRCT 2021-04-25 Iran University of Medical Sciences Apixaban in heparin-induced thrombocytopenia HIT Evaluation of the efficacy of apixaban in the treatment of heparin-induced thrombocytopenia (HIT) 2021-05-22 anticipated 30 Complete https://irct.ir/trial/55686 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. 2 Heparin-induced thrombocytopenia. Intervention group: In patients admitted to the internal ward of Rasool Akram Hospital who are diagnosed with HIT by the 4T Score, heparin will be discontinued and apixaban will be started. Based on some evidences, the dose of apixaban for the treatment of HIT is 10 mg/BD for 7 days followed by 5 mg twice daily; so we will use mentioned dose in the treatment of DVT or PE and in the prevention of stroke in non-valvular َAF. In prophylactic setting, we will use a dose of 2.5 mg twice a day, unless the patient experienced HIT with thrombosis that will receive apixaban in treatment dose of HIT.. Yes - There is a plan to make this available What will be shared: As an article When: 08-23-2021 To whom: Researchers working in academic and scientific institutions Conditions: Eligible individuals can access patient data upon written request. Where to obtain: Somayyeh Nasiripour, Assistant Professor of Clinical Pharmacy, Iran University of Medical Sciences Email: nasiripours@yahoo.com Maryam Farasatinasab, Assistant Professor of Clinical Pharmacy, Iran University of Medical Sciences Email: maryfarasati@gmail.com How to obtain: By email to responsible people Comments:

public Maryam Farasatinasab

Shahid Hemmat Highway

Tehran Iran (Islamic Republic of) 1449614535 +98 21 8214 1000 maryfarasati@gmail.com Iran University of Medical Sciences scientific Maryam Farasatinasab

Shahid Hemmat Highway

Tehran Iran (Islamic Republic of) 1449614535 +98 21 8214 1000 maryfarasati@gmail.com Iran University of Medical Sciences Iran (Islamic Republic of) 1) Age 18 years or older 2) HIT detection based on 4T Score equal to or above 4 18 years no limit Both Patients with active bleeding Patient with inherited or acquired coagulation disease or bleeding disorder Patients receiving cytochrome P-450 3A4 inhibitors or inducers Severe renal failure (CrCl <25 ml / min) Severe liver disease (including Child-Pugh B and C) The patient needs surgery History of uncorrected cerebral aneurysm, intracranial tumor or vascular accident Non-participation in research projects during the 30 days prior to the study Pregnant and lactating women Previous treatment with a non-heparin anticoagulant Covid-19 infection D69.6 Thrombocytopenia, unspecified Treatment - Surgery Intervention group: In patients admitted to the internal ward of Rasool Akram Hospital who are diagnosed with HIT by the 4T Score, heparin will be discontinued and apixaban will be started. Based on some evidences, the dose of apixaban for the treatment of HIT is 10 mg/BD for 7 days followed by 5 mg twice daily; so we will use mentioned dose in the treatment of DVT or PE and in the prevention of stroke in non-valvular َAF. In prophylactic setting, we will use a dose of 2.5 mg twice a day, unless the patient experienced HIT with thrombosis that will receive apixaban in treatment dose of HIT. Follow-up of arterial / venous thrombosis after receiving apixaban. Timepoint: If the patient becomes symptomatic. Method of measurement: Doppler ultrasound. Mortality rate. Timepoint: Daily. Method of measurement: Loss of vital signs and death of the patient. Bleeding event following the use of apixaban. Timepoint: Daily. Method of measurement: Based on the patient's symptoms such as petechiae. Iran University of Medical Sciences Approved 2020-11-01 Iran University of Medical Sciences Shahid Hemmat Highway Tehran Tehran Iran (Islamic Republic of)